Media coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has been trending somewhat negative this week, Alpha One Sentiment Analysis reports. The research group, a unit of Accern, scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a coverage optimism score of -0.12 on Alpha One’s scale. Alpha One also gave news articles about the specialty pharmaceutical company an impact score of 85 out of 100, meaning that recent news coverage is very likely to have an impact on the company’s share price in the immediate future.
Here are some of the news articles that may have effected AlphaOne’s rankings:
- AMAG Pharmaceuticals Down 29.1% Since SmarTrend Downtrend Call (AMAG) (mysmartrend.com)
- AMAG Pharmaceuticals, Inc.’s (AMAG) registers a price change of 3.08% while Heron Therapeutics, Inc.’s (HRTX … – Stocks Gallery (stocksgallery.com)
- AMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs – Nasdaq (nasdaq.com)
A number of analysts have issued reports on AMAG shares. Cantor Fitzgerald set a $25.00 target price on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, January 20th. JPMorgan Chase & Co. set a $24.00 price target on AMAG Pharmaceuticals and gave the company a “hold” rating in a research report on Tuesday, January 31st. Guggenheim reduced their price target on AMAG Pharmaceuticals from $42.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, February 2nd. Cowen and Company cut AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 3rd. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $40.00 price target (down from $45.00) on shares of AMAG Pharmaceuticals in a research report on Wednesday, February 15th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $30.00.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 18.90 on Friday. The firm’s 50-day moving average price is $21.68 and its 200 day moving average price is $25.95. AMAG Pharmaceuticals has a 52 week low of $17.90 and a 52 week high of $36.83. The company’s market cap is $662.35 million.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a net margin of 3.12% and a return on equity of 11.10%. The business had revenue of $139.47 million for the quarter, compared to analysts’ expectations of $150.32 million. During the same period in the prior year, the company posted ($0.22) EPS. The firm’s revenue was up 27.6% on a year-over-year basis. On average, equities research analysts forecast that AMAG Pharmaceuticals will post $5.13 EPS for the current year.
In related news, SVP Julie Krop sold 1,891 shares of the company’s stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total transaction of $46,234.95. Following the completion of the sale, the senior vice president now owns 36,777 shares of the company’s stock, valued at approximately $899,197.65. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “AMAG Pharmaceuticals (AMAG) Getting Somewhat Negative News Coverage, AlphaOne Reports” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://transcriptdaily.com/2017/05/20/somewhat-negative-press-coverage-very-likely-to-impact-amag-pharmaceuticals-amag-stock-price-updated-updated.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.